Seventeen percent of BRCA and UCEC express PGR and 9.4% of BRCA express ERBB2 in our cohort, reflecting the FDA-approved use of anti-estrogen hormone therapy and HER-2 inhibitors, respectively, in these cancer types. Here, ERBB2 is linked to cancer.